An observational study of serum and cerebrospinal fluid concentrations of osimertinib for the treatment of lung cancer harboring EGFR activating and T790M mutations.
Phase of Trial: Phase IV
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 18 Oct 2016 New trial record